Last reviewed · How we verify

DUOSTIM

Centre Hospitalier Intercommunal Creteil · Phase 3 active Small molecule

DUOSTIM is a dual stimulation protocol combining FSH and LH for controlled ovarian hyperstimulation in assisted reproductive technology.

DUOSTIM is a dual stimulation protocol combining FSH and LH for controlled ovarian hyperstimulation in assisted reproductive technology. Used for Controlled ovarian hyperstimulation in assisted reproductive technology (ART) / in vitro fertilization (IVF), Ovulation induction in infertility treatment.

At a glance

Generic nameDUOSTIM
Also known asSame monthly cycle
SponsorCentre Hospitalier Intercommunal Creteil
Drug classGonadotropin combination therapy
TargetFSH receptor and LH receptor
ModalitySmall molecule
Therapeutic areaReproductive Medicine / Fertility
PhasePhase 3

Mechanism of action

DUOSTIM employs simultaneous stimulation with follicle-stimulating hormone (FSH) and luteinizing hormone (LH) to promote multiple follicle development during in vitro fertilization cycles. This dual-hormone approach aims to improve oocyte yield and embryo quality compared to FSH-alone protocols, particularly in poor responders or women of advanced reproductive age.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: